Type II anti-CD20 antibody obinutuzumab outperforms rituximab in lupus trials, review finds

A new comparative review argues that a second-generation B-cell-depleting antibody, obinutuzumab, has overturned two decades of pessimism about B-cell depletion therapy for systemic lupus erythematosus (SLE) and lupus nephritis (LN). The review, published in Discover Immunity on 11 July 2026, synthesises randomised controlled trial, cohort and mechanistic evidence on the two anti-CD20 antibodies and concludes that the type II glycoengineered antibody achieved in Phase 3 trials what the older type I antibody rituximab could not: statistically significant superiority over placebo in both renal and extra-renal lupus.

The authors, Shihshuan Fang and Shenghan Chen, conducted a narrative search of PubMed from database inception through March 2026, identifying eight trials that met their inclusion criteria of adult patients with SLE or LN treated with rituximab or obinutuzumab. Their primary outcomes of interest were SRI-4 response rates, a composite measure of disease activity requiring at least a four-point drop in the SLEDAI-2K score without significant worsening in physician assessment or new severe organ domain activity, and complete renal response (CRR), defined by proteinuria falling to 0.5 mg/mg or less with preserved kidney function and quiet urinary sediment. Because trial designs, populations and follow-up durations varied widely, the authors deliberately avoided formal meta-analytic pooling and instead presented a stratified narrative synthesis.

The rituximab story begins with two pivotal Phase 3 failures. In the EXPLORER trial, 257 patients with moderately to severely active non-renal SLE were randomised to rituximab or placebo on top of background immunosuppressants such as mycophenolate mofetil, azathioprine or methotrexate. Despite robust peripheral B-cell depletion in most treated patients, the trial missed its primary BILAG-based composite endpoint at week 52 and no secondary endpoint reached significance. In the LUNAR trial, 144 patients with class III or IV lupus nephritis received rituximab or placebo added to mycophenolate and corticosteroids; the overall renal response rate at week 52 was 56.9 percent versus 45.8 percent with placebo, a difference that was not statistically significant, and complete renal response rates were actually numerically lower with rituximab at 26 percent versus 30 percent. Serological markers such as anti-dsDNA antibodies and complement levels did improve, suggesting biological activity without commensurate clinical benefit at the endpoint level.

Notably, the review cites a methodological fragility index analysis showing that the EXPLORER and LUNAR negative results were statistically robust rather than artefacts of underpowered data, implying that the failures likely reflect genuine pharmacological limitations of rituximab in lupus rather than poor trial conduct. Yet rituximab never left the clinic. Real-world registries and long-term observational data report response rates of up to 75 percent in refractory SLE patients followed for ten years or more, and both ACR and EULAR guidelines have recommended the drug for refractory lupus nephritis. The review attributes this discordance to factors including highly selected treatment-refractory populations, flexible dosing in practice, and disease heterogeneity that dilutes responder subgroups in intention-to-treat analyses.

Obinutuzumab differs from rituximab in two engineered respects. First, an elbow-hinge modification in the Fab region changes the binding orientation so that CD20 is not redistributed into cholesterol-rich lipid rafts, avoiding the internalisation and trogocytosis-driven antigenic modulation that progressively strips rituximab off the B-cell surface. Second, afucosylation of the Fc-region glycan at Asn297 increases affinity for the activating receptor Fc-gamma-RIIIa by roughly 50-fold, dramatically enhancing antibody-dependent cellular cytotoxicity by natural killer cells and antibody-dependent cellular phagocytosis by macrophages. In vitro assays using patient-derived SLE cells showed obinutuzumab was at least twice as efficient as rituximab at killing B cells, with the advantage extending to switched memory B cells, a subset enriched for pathogenic autoreactive clones and linked to poor rituximab response. Preclinical work in lupus-prone MRL/lpr mice expressing human CD20 found deeper depletion, reduced glomerulonephritis scores and lower autoantibody titres with obinutuzumab.

The clinical results are striking. In the Phase 2 NOBILITY trial, 125 patients with biopsy-proven proliferative LN received obinutuzumab or placebo on background mycophenolate and steroids; complete renal response at week 52 was 35 percent versus 23 percent, missing conventional significance with the exploratory alpha threshold of 0.2, but at week 104 the difference reached 41 percent versus 23 percent, statistically significant at p = 0.026. The Phase 3 REGENCY trial, published in 2025 in 271 adults with active proliferative LN, then confirmed CRR at week 76 of 46.4 percent versus 33.1 percent with placebo, an adjusted difference of 13.4 percentage points, and secured US FDA approval of obinutuzumab for active LN. Most recently, the Phase 3 ALLEGORY trial, published in March 2026 in 303 adults with active extra-renal SLE, reported SRI-4 response of 76.7 percent versus 53.5 percent with placebo, an adjusted difference of 23.1 percentage points, with superiority on all key secondary endpoints including BICLA response, glucocorticoid sparing and time to flare.

B-cell depletion kinetics may explain the divergence. In LUNAR, rituximab achieved peripheral depletion below five CD19-positive cells per microlitre in roughly 80 percent of patients by week 24, whereas obinutuzumab achieved near-complete depletion in more than 95 percent of patients by week 4, sustained through at least week 52 in the majority. Incomplete depletion is an established predictor of rituximab non-response and earlier relapse, and the review argues this pharmacodynamic difference directly accounts for the superior clinical outcomes, particularly since the obinutuzumab nephritis trials shared design features with LUNAR, including background mycophenolate and steroid regimens and similar renal endpoints.

Safety profiles overlap but differ in emphasis. Both drugs carry class risks of infusion-related reactions, infection susceptibility related to hypogammaglobulinaemia, late-onset neutropenia and rare opportunistic infections. Obinutuzumab caused first-infusion reactions in roughly 40 percent of trial patients, generally mild to moderate and manageable with pre-medication, while serious infections and adverse events did not differ from placebo in the trials. The review raises a theoretical concern that deeper depletion may provoke more pronounced BAFF rebound and a higher risk of late-onset neutropenia, and it highlights a case series of severe neutropenia and persistent anaemia in young patients with glomerular diseases treated with obinutuzumab monotherapy outside trials. Immunogenicity favours the newer agent: anti-drug antibodies to rituximab arose in 10 to 25 percent of SLE trial patients and in 37.8 percent of patients after first real-world exposure, associated with accelerated drug clearance, inadequate depletion and relapse, whereas anti-obinutuzumab antibodies were infrequent across all three lupus trials.

The authors are careful to flag the limits of their synthesis. No head-to-head randomised comparison of the two antibodies exists, so all efficacy contrasts are indirect, drawn from separate trials in different populations and timepoints. The mechanistic claims about trogocytosis and complement dependence rest largely on preclinical and onco-haematology data; whether the hypocomplementaemic milieu of active lupus genuinely impairs rituximab-mediated complement-dependent cytotoxicity remains formally undemonstrated. Long-term outcomes such as end-stage renal disease, damage accrual and mortality are not yet available for obinutuzumab, trial populations were predominantly Latin American and European, and as a narrative rather than systematic review the work is subject to selection and interpretation bias. The 2025 EULAR recommendations for SLE with kidney involvement, updated after EMA approval of obinutuzumab for LN in December 2025, now include the drug as an option for active LN, and the review calls for head-to-head trials, biomarker-stratified patient selection and long-term safety surveillance to define the optimal sequencing of these two B-cell-depleting strategies.

Subject of Research: Comparative efficacy of type I versus type II anti-CD20 B-cell-depleting antibodies in systemic lupus erythematosus and lupus nephritis

Article Title: Obinutuzumab versus rituximab in systemic lupus erythematosus and lupus nephritis: a systematic comparative review of type I and type II anti-CD20 strategies

Article References: Fang, S., & Chen, S. (2026). Obinutuzumab versus rituximab in systemic lupus erythematosus and lupus nephritis: a systematic comparative review of type I and type II anti-CD20 strategies. Discover Immunity, 3(1), Article 13. https://doi.org/10.1007/s44368-026-00032-z

Image Credits: AI Generated

DOI: 10.1007/s44368-026-00032-z

Keywords: systemic lupus erythematosus, lupus nephritis, obinutuzumab, rituximab, anti-CD20, B-cell depletion, REGENCY trial, ALLEGORY trial, complete renal response, SRI-4, immunogenicity, monoclonal antibodies